A5066584153- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- PARP inhibition in cancer therapy
- Bioinformatics and Genomic Networks
- Cancer Immunotherapy and Biomarkers
- Cervical Cancer and HPV Research
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Sarcoma Diagnosis and Treatment
- Cancer-related gene regulation
- Prostate Cancer Treatment and Research
- Intraperitoneal and Appendiceal Malignancies
- Radiomics and Machine Learning in Medical Imaging
- Estrogen and related hormone effects
- Genetics, Bioinformatics, and Biomedical Research
- Reproductive System and Pregnancy
- Lung Cancer Treatments and Mutations
- Advances in Oncology and Radiotherapy
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- Adenosine and Purinergic Signaling
- Cancer, Lipids, and Metabolism
University of Chicago
2020-2025
University of Chicago Medical Center
2023-2024
University of Chicago Medicine Comprehensive Cancer Center
2023
Gynecologic Oncology Group
2021
The University of Texas MD Anderson Cancer Center
2016-2019
AstraZeneca (Brazil)
2019
Karyopharm Therapeutics (United States)
2019
Clovis Oncology (United Kingdom)
2019
Pfizer (United States)
2019
Princess Margaret Cancer Centre
2018
The prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) endometrial cancer patients is still unclear. Our aim was to assess the value with low risk who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared node negative patients.
High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular increasingly being used to guide cancer patient care, especially in advanced incurable cancers. However, navigating the scientific literature make evidence-based decisions based on results overwhelming for many oncology clinicians researchers. The Personalized Cancer Therapy website (www.personalizedcancertherapy.org) was created provide online resource researchers facilitate...
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) been approved by the US Food and Drug Administration for of cervical cancer endometrial cancer, offering durable responses some patients. In addition, many immunotherapy strategies are under investigation earlier stages disease or in other cancers, such as ovarian rare tumors. While integration ICIs into standard care has improved outcomes patients, their use...
OBJECTIVE: To estimate whether gastrointestinal-type chemotherapy was associated with improved survival compared standard gynecologic regimens for women ovarian mucinous carcinoma. METHODS: We conducted a retrospective cohort study of patients carcinoma who received postoperative adjuvant at two academic centers. Demographic and clinical information abstracted from the medical records. Gastrointestinal-type contained 5-fluorouracil, capecitabine, irinotecan, or oxaliplatin. Gynecologic...
The COVID-19 pandemic has created new challenges for ovarian cancer survivors. This study aims to evaluate the psychologic morbidity and alterations in medical care caused by pandemic.Advanced-stage survivors at our institution were contacted participation a cross-sectional telephone-based quantitative survey assessing pandemic-related morbidity. Psychologic domains using validated measures explored: health-related quality of life (HRQOL; functional assessment therapy [FACT-G7]), anxiety...
Historically, microsatellite instability testing has been used to identify patients with endometrial cancer Lynch syndrome. It currently is also being those individuals who may be candidates for immunotherapy.
In many tumors, CD73 (NT5E), a rate-limiting enzyme in adenosine biosynthesis, is upregulated by TGF-β and drives tumor progression. Conversely, downregulated endometrial carcinomas (EC) despite TGF-β-rich environment. Through gene expression analyses of normal endometrium samples the uterine cancer TCGA data set genetic pharmacological studies, we discovered loss shifts TGF-β1 from suppressor to promoter EC. epithelial integrity vivo vitro early stage EC cells. With CD73, TGF-β1-mediated...
• Metastatic SCC arising from the ovary is rare, and optimal treatment unknown. Pembrolizumab successfully treated a patient with metastatic SCC. Patients on pembrolizumab should be monitored for immune-related adverse events.
Abstract Background: Preclinical data from our team demonstrated that MEK inhibition increases antitumor efficacy of PARP inhibitors in tumors with Ras pathway alterations. We sought to identify dose limiting toxicities (DLTs) and maximum tolerated (MTD) olaparib selumetinib combination solid Methods: Olaparib were given orally twice daily. Dose escalation three planned levels (DL) was performed using the modified toxicity probability interval 2 design assessed by CTCAE v4.03. RECIST...